Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoBREASTIM
2022-502311-12-00Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and vusolimogene oderparepvec in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Primary endpoints: Safety run-in: incidence, nature and severity of adverse events and Residual cancer burden RCB 0-1 rate at surgery in patients with no increase in ctDNA after cycle 3. Started Apr 2024; status: completed.
02
Drugs
atezolizumabvusolimogene oderparepvec
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-502311-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502311-12-00.